Today: 19 October 2025
Subscribe
PACS Group (NYSE:PACS) Pops After NYSE Reprieve—Is the Nursing‑Home Giant Finally Turning the Corner? [Sep 26, 2025]
 ·  ·  ·  · 

PACS Group (NYSE:PACS) Pops After NYSE Reprieve—Is the Nursing‑Home Giant Finally Turning the Corner? [Sep 26, 2025]

by
26 September 2025

Key facts (as of Sep 26, 2025)

  • Price/Move: $13.98 (+10.2% intraday); day range $12.69–$14.21; ~1.37M shares traded.
  • Today’s tape: Coverage notes shares +5% intraday during Friday’s session.  [1]
  • Latest corporate milestone: NYSE grants listing extension to Nov. 19, 2025 while PACS completes restatements and becomes current on SEC filings.  [2]
  • Operational snapshot (preliminary, 1H25): 316 facilities across 17 states; 88.9% occupancy vs. 78% industry; 64.6% of SNFs at 4–5‑star CMS QM; cash $294.2M.  [3]
  • Accounting update: PACS will restate 1H24 results—prelim. revenue overstatements of ~$15–17M (Q1) and ~$46–48M (Q2) tied to Medicare Part B recognition for certain services.  [4]
  • Governance: CFO Derick Apt resigned (Sep 2) after the audit committee found he accepted a “series of high‑value” gifts; co‑founder Mark Hancock named interim CFO (Sep 3).  [5]
  • Legal overhang: Multiple securities‑law investigations/class‑action efforts continue; Pomerantz LLP opened a fresh investigation Sep 24.  [6]
  • Street view (12‑mo targets): Average target ~$31–$35 (range $18–$50) across trackers (MarketBeat/Barron’s/Yahoo/TipRanks).  [7]

In‑depth report

What moved the stock this week

PACS rallied into the Sep 26 close with intraday gains reported by market trackers. The surge follows two mid‑September catalysts: (1) NYSE’s listing extension to Nov 19, 2025, giving the company runway to finish restatements and regain compliance; and (2) a series of governance actions, including a CFO change.  [8]

Management messaging turned incrementally constructive. CEO Jason Murray said PACS expects to report “record revenue and Adjusted EBITDA for the first six months of 2025” once filings are current. Interim Chief Compliance Officer Kathy Lauer added that PACS is “taking the right steps to best position the company” during its compliance overhaul.  [9]

Company snapshot

PACS Group is a post‑acute and senior‑living platform. As of June 30, 2025, subsidiaries operated 316 facilities with 32,208 SNF beds and 2,419 AL beds in 17 states. Occupancy was 88.9% (vs. industry ~78%), with 64.6% of SNFs scoring 4–5 stars on CMS Quality Measures—indicators management points to as proof of operating momentum. PACS also reported $294.2M cash on hand at June 30, 2025. All figures are preliminary and subject to the completion of restatements.  [10]

Where the risks came from (and what’s left to fix)

  • Revenue recognition & Medicare billing: On Jun 16, 2025, PACS said Part B respiratory and certain therapy services were incorrectly recognized as revenue in 1H24, resulting in prelim. overstatements of $15–17M (Q1) and $46–48M (Q2). The affected 2024 quarters “should no longer be relied upon,” and 10‑Q/10‑K filings for late‑2024 and 1Q25 remain outstanding.  [11]
  • Governance & leadership: On Sep 2, CFO Derick Apt resigned after the board concluded he had accepted a “series of high‑value items” from business associates—violating the code of conduct. Co‑founder Mark Hancockreturned as interim CFO on Sep 3. The board also disclosed a president‑level departure in August.  [12]
  • Listing compliance: NYSE granted another extension through Nov 19, 2025, keeping shares listed while PACS finishes restatements and becomes current with the SEC. Failure to meet that date risks delisting.  [13]
  • Litigation: Multiple law firms (e.g., Pomerantz) are investigating or have filed actions related to the restatements and disclosures; this keeps legal risk alive even if filings are completed.  [14]

What experts and primary sources are saying

  • CEO Jason Murray (Sep 11): “We expect to report record revenue and Adjusted EBITDA for the first six months of 2025 [once current on filings].”  [15]
  • Interim CCO Kathy Lauer: PACS is “taking the right steps” to enhance compliance and controls.  [16]
  • CFO.com (Sep 10) on the CFO change: the board said Apt accepted a “series of high‑value items”; Mark Hancock (co‑founder, prior CFO) was appointed interim CFO.  [17]

Street consensus, forecasts & how to read them

  • Targets: Aggregators show a $31–$35 average 12‑month target (high $50, low $18), implying >100% upside from ~$14. Sources vary on analyst counts due to coverage changes after the restatement announcement. Treat these with caution until audited financials are current.  [18]
  • Technical context: A tracker shows 50‑day SMA ~$11.36 and 200‑day SMA ~$11.08, so today’s move keeps shares above both medium‑term trend lines.  [19]

Operating pulse & industry backdrop

PACS’s preliminary metrics paint a picture of strong facility‑level performance (high occupancy, better‑than‑industry CMS quality scores) and balance‑sheet liquidity ($294.2M cash as of 6/30/25) that could support accretive acquisitions once filings normalize. That said, billing risk (Medicare Part B) and internal control enhancements remain priority workstreams through the NYSE deadline.  [20]

Timeline of recent events

  • Aug 15, 2025: President P.J. (Peter) Sanford resigns (consulting arrangement disclosed).  [21]
  • Sep 2–3, 2025: CFO Apt resigns; Hancock appointed interim CFO.  [22]
  • Sep 11, 2025: NYSE extension to Nov 19, 2025; management previews record 1H25 revenue & Adj. EBITDA; updated operating stats released.  [23]
  • Sep 24, 2025: Pomerantz begins new shareholder investigation.  [24]
  • Sep 26, 2025: Stock trades higher intraday; liquidity and trend remain in focus.  [25]

Valuation & scenarios (qualitative, given pending restatements)

  • Bull case: Restated financials filed on time; NYSE compliance restored; quality/occupancy metrics hold; Street re‑rates on cleaner earnings quality and continued tuck‑in acquisitions. Targets clustered around $31–$35 (high $50) become more credible if PACS validates record 1H25 Profitability.  [26]
  • Base case: Filings come through near deadline, but legal/oversight costs and Medicare billing guardrails compress margins; shares trade between trend and low‑end targets (e.g., $18–$31).  [27]
  • Bear case: Filing delays extend or findings worsen; NYSE compliance lapsed; litigation costs escalate; multiple compression toward single‑digit billions or delisting overhang weighs on liquidity.  [28]

What to watch next (date‑driven)

  1. Before Nov 19, 2025: Delivery of restated 1H24 financials and all delinquent 2024–1Q25/2Q25 reports to regain NYSE compliance.  [29]
  2. Management bench: Permanent CFO selection and any further board/committee changes.  [30]
  3. Legal docket: Progress in shareholder actions and any regulatory updates tied to Medicare Part B billing practices.  [31]
  4. Operating metrics: Occupancy, skilled‑mix, and acquisition cadence in 2H25; confirmation of “record” 1H25 revenue/Adj. EBITDA once filings resume.  [32]

Sources & further reading

  • Quote/metrics & NYSE extension (Sep 11): PACS IR / Business Wire press release with interim operating metrics and management quotes.  [33]
  • Restatement detail (Jun 16): PACS IR press release explaining recognition errors and preliminary overstatements.  [34]
  • CFO resignation (Sep 8 filing; Sep 10 coverage): PACS 8‑K and CFO.com/Healthcare Dive article on the code‑of‑conduct violations.  [35]
  • Share price/quote page: Yahoo Finance overview and analysis pages for PACS.  [36]
  • Analyst targets/consensus: MarketBeat forecast page; Barron’s research snapshot; TipRanks consensus.  [37]
  • Today’s trading color: MarketBeat intraday note.  [38]
  • Additional background: Reuters coverage of the 2024 IPO.  [39]

Quick take

PACS looks fundamentally busy and operationally resilient, but the investment case hinges on execution between now and Nov 19: finish the restatements, restore timely reporting, and steady governance. If PACS clears those hurdles, Street targets suggest ample upside; if not, listing and litigation risk remain the swing factors.

This report is for information only and not investment advice.

References

1. www.marketbeat.com, 2. www.businesswire.com, 3. www.businesswire.com, 4. ir.pacs.com, 5. ir.pacs.com, 6. www.globenewswire.com, 7. www.marketbeat.com, 8. www.marketbeat.com, 9. www.businesswire.com, 10. www.businesswire.com, 11. ir.pacs.com, 12. ir.pacs.com, 13. www.businesswire.com, 14. www.globenewswire.com, 15. www.businesswire.com, 16. www.businesswire.com, 17. www.cfo.com, 18. www.marketbeat.com, 19. www.marketbeat.com, 20. www.businesswire.com, 21. ir.pacs.com, 22. ir.pacs.com, 23. www.businesswire.com, 24. www.globenewswire.com, 25. www.marketbeat.com, 26. www.businesswire.com, 27. www.marketbeat.com, 28. www.businesswire.com, 29. www.businesswire.com, 30. ir.pacs.com, 31. www.globenewswire.com, 32. www.businesswire.com, 33. www.businesswire.com, 34. ir.pacs.com, 35. ir.pacs.com, 36. finance.yahoo.com, 37. www.marketbeat.com, 38. www.marketbeat.com, 39. www.reuters.com

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

  1. BlackRock’s Bitcoin ETF Smashes $100B Mark as Uptober Rally Stalls – Inside IBIT’s Wild Ride
  2. Tesla Stock’s Wild Ride: TSLA Soars on Record Sales, Sinks on ‘Budget’ EV News – What’s Next?
  3. Plug Power Stock Skyrockets 170% on Hydrogen Hype – Can PLUG’s Rally Hold or Fizzle?
  4. Bitcoin Boom Sends Bitfarms (BITF) Stock Soaring – New $500M Deal & AI Pivot Fuel Rally

Related Articles

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update
Previous Story

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Iran’s Rial Crisis Deepens: USD Soars Past 1.08 Million on Black Market Amid Sanctions Fears (قیمت دلار)
Next Story

Iran’s Rial Crisis Deepens: USD Soars Past 1.08 Million on Black Market Amid Sanctions Fears (قیمت دلار)

Stock Market Today

  • Danaher Valuation in Focus After 8% 1-Month Gain
    October 19, 2025, 2:38 AM EDT. Danaher (DHR) has posted an 8% gain over the last month and about 10% in the past quarter, signaling renewed investor interest in the life sciences space. Yet the stock's 1-year total return remains negative, underscoring a long-term backdrop that still needs improvement. Analysts frame a bullish case around addressable market expansion from rising global healthcare investment, precision medicine, and AI-assisted diagnostics, which could drive margin expansion and higher EBITDA. The latest narrative pegs a fair value near $244.50, suggesting the stock could be undervalued despite a current price around $209. However, elevated valuation multiples (P/E ~43.9x) versus peers and broader Geopolitical/China risks could cap upside. Investors should weigh near-term momentum against the longer-run growth trajectory and potential policy shocks.
  • Matthews International Sells $18 Million Sea Limited Stake; Portfolio Rebalancing Amid Sea Rally
    October 19, 2025, 1:52 AM EDT. On Oct. 16, 2025, Matthews International Capital Management disclosed the sale of 106,055 shares of Sea Limited (SE) in Q3 2025, an estimated $18.17 million trade based on the quarter's average price. The fund held 213,226 Sea Limited shares as of Sept. 30, 2025, valued at $38.11 million at quarter-end, representing 8.87% of 13F AUM and remaining its 2nd-largest holding. At Sept. 30, 2025, its top holdings included PDD Holdings, Sea Limited, Legend Biotech, Trip.com Group, and Kanzhun. Sea's stock traded around $162.65 on Oct. 16, 2025, up 63.7% YoY and ahead of the S&P 500 by about 54 percentage points over the period. Sea operates Garena, Shopee, and SeaMoney across Southeast Asia and beyond. Matthews' sale appears to be a rebalancing move rather than a negative view.
  • Matthews Sells $18M of Sea Limited Shares, Yet Sea Remains Core Position
    October 19, 2025, 1:50 AM EDT. Matthews International Capital Management disclosed in an Oct. 16, 2025 filing that it sold 106,055 shares of Sea Limited (SE) in Q3, valued at about $18.17 million. The trade reduced Matthews' Sea stake to 213,226 shares, worth roughly $38.11 million as of Sept. 30, 2025, and cut Sea to about 8.87% of AUM while keeping SE as the fund's 2nd-largest holding. Price action around the filing showed Sea at $162.65 on Oct. 16, up about 63.7% year over year and ahead of the S&P 500 by roughly 54 percentage points over that period. Matthews previously built a foothold in Sea in early 2024 when shares traded between $50-$70, and the stock has since tripled, leaving Sea a material pillar in the portfolio.
  • Ameriprise Financial (AMP) Still Undervalued as Growth Catalysts Loom Despite Pullback
    October 19, 2025, 12:44 AM EDT. Ameriprise Financial (AMP) has inched higher by about 0.5% in the latest session, though shares are down roughly 3% over the last month and 11.3% year-to-date. Yet long-term holders have seen strong returns: total shareholder return of about 83.9% over 3 years and 199% over 5 years. The stock trades at about 37% below its estimated intrinsic value and roughly 17% under analyst price targets, with a note that the current price sits in front of a fair value estimate of $550.27 (UNDERVALUED). Potential catalysts include expansion of banking products ( CDs, HELOCs, checking ), and stronger adviser recruitment/tech platforms boosting net interest income and wealth management share. Risks include volatility and asset outflows. Investors should review the underlying assumptions shaping the upside.
  • JMIC Disposes $7.5M of Adobe in Q3 2025: Implications for ADBE
    October 19, 2025, 12:14 AM EDT. Joel R Mogy Investment Counsel disclosed a Q3 2025 sale of 20,929 Adobe shares, roughly $7.51 million, reducing its ADBE stake to 50,664 shares and bringing the position to about 0.98% of AUM ($1.83B) as of Sept. 30, 2025. The trim follows two prior quarters of selling and leaves JMIC with a smaller, still sizable stake in a stock down about 34.9% year over year and ~52% off its all-time high. Adobe remains among the fund's top holdings, but its weight has declined from a two-year peak of 2.5%. As AI-related headwinds and competition reshape the software landscape, investors will weigh whether the stock's long-term subscription model can sustain growth amid a broad market pullback for tech.
Go toTop